An in silico DNA vaccine against Listeria monocytogenes

Vaccine

Volumn 29, Issue 40, 2011, Pages 6948-6958

  Jahangiri, Abolfazl ^a   Rasooli, Iraj ^a   Gargari, Seyed Latif Mousavi ^a   Owlia, Parviz ^a   Rahbar, Mohammad Reza ^a   Amani, Jafar ^b   Khalili, Saeed ^c  

^a SHAHED UNIVERSITY   (Iran)

^b BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TARBIAT MODARES UNIVERSITY   (Iran)

Author keywords

DNA vaccine; Immunity; In silico; Listeria monocytogenes; Listeriolysin O; T cell

Indexed keywords

ANTIGEN; CPG OLIGODEOXYNUCLEOTIDE; DNA VACCINE; EPITOPE; GLUTAMIC ACID; HLA ANTIGEN; LISTERIOLYSIN O; MESSENGER RNA; PROLINE; SERINE; THREONINE; UBIQUITIN;

ARTICLE; BIOINFORMATICS; CODON; COMPUTER MODEL; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; GENE EXPRESSION; HLA SYSTEM; IMMUNE RESPONSE; LISTERIA MONOCYTOGENES; LISTERIOSIS; MYRISTYLATION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN GLYCOSYLATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; RNA STABILITY; RNA STRUCTURE; SECRETORY PATHWAY; SEQUENCE ANALYSIS; TRANSLATION INITIATION;

ALLERGENS; AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL TOXINS; COMPUTATIONAL BIOLOGY; CPG ISLANDS; GENE EXPRESSION; GENES, MHC CLASS I; HEAT-SHOCK PROTEINS; HEMOLYSIN PROTEINS; HLA ANTIGENS; HUMANS; IMMUNODOMINANT EPITOPES; LISTERIA MONOCYTOGENES; PROTEIN PROCESSING, POST-TRANSLATIONAL; RNA, MESSENGER; SECRETORY PATHWAY; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, DNA;

EID: 80052342097     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.07.040     Document Type: Article

References (129)

1. Lorber B., Listeriosis Clinical Infectious Diseases 1997, 24(January (1)):1-11.
2. Meng J., Doyle M. Emerging issues in microbiological food safety. Annual Review of Nutrition 1997, 17(1):255-275.
3. Farber J., Peterkin P. Listeria monocytogenes, a food-borne pathogen. Microbiology and Molecular Biology Reviews 1991, 55(3):476.
4. Czuprynski C. Listeria monocytogenes: silage, sandwiches and science. Animal Health Research Reviews 2005, 6(02):211-217.
5. Cossart P., Portnoy D. The cell biology of invasion and intracellular growth by Listeria monocytogenes. Gram-Positive Pathogens 2000, 507-513.
6. Geoffroy C., Gaillard J.L., Alouf J.E., Berche P. Purification, characterization, and toxicity of the sulfhydryl-activated hemolysin listeriolysin O from Listeria monocytogenes. Infection and Immunity 1987, 55(7):1641.
7. Vazquez-Boland J.A, Kuhn M., Berche P., Chakraborty T., Dominguez-Bernal G., Goebel W., et al. Listeria pathogenesis and molecular virulence determinants. Clinical Microbiology Reviews 2001, 14(3):584.
8. Pizarro-Cerdá J., Cossart P. Subversion of cellular functions by Listeria monocytogenes. The Journal of Pathology 2006, 208(2):215-223.
9. Suárez M., González Zorn B., Vega Y., Chico Calero I., Vázquez Boland J. A role for ActA in epithelial cell invasion by Listeria monocytogenes. Cellular Microbiology 2001, 3(12):853-864.
10. Gedde M.M., Higgins D.E., Tilney L.G., Portnoy D.A. Role of listeriolysin O in cell-to-cell spread of Listeria monocytogenes. Infection and Immunity 2000, 68(2):999.
11. Decatur A.L, Portnoy D.A. A PEST-like sequence in listeriolysin O essential for Listeria monocytogenes pathogenicity. Science 2000, 290(5493):992.
12. Lety M.A., Frehel C., Dubail I., Beretti J.L., Kayal S., Berche P., et al. Identification of a PEST like motif in listeriolysin O required for phagosomal escape and for virulence in Listeria monocytogenes. Molecular Microbiology 2001, 39(5):1124-1139.
13. Lety M.A., Frehel C., Berche P., Charbit A. Critical role of the N terminal residues of listeriolysin O in phagosomal escape and virulence of Listeria monocytogenes. Molecular Microbiology 2002, 46(2):367-379.
14. Schnupf P., Portnoy D.A. Listeriolysin O: a phagosome-specific lysin. Microbes and Infection 2007, 9(10):1176-1187.
15. Michel E., Reich K., Favier R., Berche P., Cossart P. Attenuated mutants of the intracellular bacterium Listeria monocytogenes obtained by single amino acid substitutions in listeriolysin O. Molecular Microbiology 1990, 4(12):2167-2178.
16. Demuth A., Chakraborty T., Krohne G., Goebel W. Mammalian cells transfected with the listeriolysin gene exhibit enhanced proliferation and focus formation. Infection and Immunity 1994, 62(11):5102.
17. Coconnier M.H, Dlissi E., Robard M., Laboisse C.L., Gaillard J.L., Servin A.L. Listeria monocytogenes stimulates mucus exocytosis in cultured human polarized mucosecreting intestinal cells through action of listeriolysin O. Infection and Immunity 1998, 66(8):3673.
18. Kayal S., Lilienbaum A., Poyart C., Memet S., Israel A., Berche P. Listeriolysin O dependent activation of endothelial cells during infection with Listeria monocytogenes: activation of NF B and upregulation of adhesion molecules and chemokines. Molecular Microbiology 1999, 31(6):1709-1722.
19. Tang P., Rosenshine I., Finlay B. Listeria monocytogenes, an invasive bacterium, stimulates MAP kinase upon attachment to epithelial cells. Molecular Biology of the Cell 1994, 5(4):455.
20. Wadsworth S.J., Goldfine H. Listeria monocytogenes phospholipase C-dependent calcium signaling modulates bacterial entry into J774 macrophage-like cells. Infection and Immunity 1999, 67(4):1770.
21. Drevets D.A Listeria monocytogenes virulence factors that stimulate endothelial cells. Infection and Immunity 1998, 66(1):232.
22. Krull M., Nost R., Hippenstiel S., Domann E., Chakraborty T., Suttorp N. Listeria monocytogenes potently induces up-regulation of endothelial adhesion molecules and neutrophil adhesion to cultured human endothelial cells. The Journal of Immunology 1997, 159(4):1970.
23. Sibelius U., Rose F., Chakraborty T., Darji A., Wehland J., Weiss S., et al. Listeriolysin is a potent inducer of the phosphatidylinositol response and lipid mediator generation in human endothelial cells. Infection and Immunity 1996, 64(2):674.
24. Guzmán C.A, Domann E., Ronde M., Bruder D., Darji A., Weiss S., et al. Apoptosis of mouse dendritic cells is triggered by listeriolysin, the major virulence determinant of Listeria monocytogenes. Molecular Microbiology 1996, 20(1):119-126.
25. Sibelius U., Schulz E.C., Rose F., Hattar K., Jacobs T., Weiss S., et al. Role of Listeria monocytogenes exotoxins listeriolysin and phosphatidylinositol-specific phospholipase C in activation of human neutrophils. Infection and Immunity 1999, 67(3):1125.
26. Kuhn M., Goebel W. Induction of cytokines in phagocytic mammalian cells infected with virulent and avirulent Listeria strains. Infection and Immunity 1994, 62(2):348.
27. Nishibori T., Xiong H., Kawamura I., Arakawa M., Mitsuyama M. Induction of cytokine gene expression by listeriolysin O and roles of macrophages and NK cells. Infection and Immunity 1996, 64(8):3188.
28. Hess J., Schaible U., Raupach B., Kaufmann S.H.E. Exploiting the immune system: toward new vaccines against intracellular bacteria. Advances in Immunology 2000, 75:1-88.
29. Kaufmann S.H.E., Follows G.A., Munik M.E. Immunity to intracellular bacteria. Memorias do Instituto Oswaldo Cruz 1992, 87:91-94.
30. Russell D. Cellular microbiology. Where to stay inside the cell: a homesteader's guide to intracellular parasitism 2000, American Society for Microbiology, Washington, DC, p. 131-52.
31. Toshi N., Yukio K. Induction of specific CD8+ T Cells against intracellular bacteria by CD8+ T-cell-oriented immunization approaches. Journal of Biomedicine and Biotechnology 2010, 2010.
32. Zenewicz L.A., Shen H. Innate and adaptive immune responses to Listeria monocytogenes: a short overview. Microbes and Infection 2007, 9(10):1208-1215.
33. Pertmer T.M, Roberts T.R., Haynes J.R. Influenza virus nucleoprotein-specific immunoglobulin G subclass and cytokine responses elicited by DNA vaccination are dependent on the route of vector DNA delivery. Journal of Virology 1996, 70(9):6119.
34. Pamer E.G., Harty J.T., Bevan M.J. Precise prediction of a dominant class I MHC-restricted epitope of Listeria monocytogenes. Nature 1991, 353(6347):852.
35. Harty J., Bevan M. CD81T cells specific for a single nonamer epitope of Listeria monocytogenes are protective in vivo. Journal of Experimental Medicine 1992, 175:1531-1538.
36. Uchijima M., Yoshida A., Nagata T., Koide Y. Optimization of codon usage of plasmid DNA vaccine is required for the effective MHC class I-restricted T cell responses against an intracellular bacterium. The Journal of Immunology 1998, 161(10):5594.
37. Berche P., Gaillard J.L., Geoffroy C., Alouf J.E. T cell recognition of listeriolysin O is induced during infection with Listeria monocytogenes. The Journal of Immunology 1987, 139(11):3813.
38. Bouwer H., Nelson C.S., Gibbins B.L., Portnoy D.A., Hinrichs D.J. Listeriolysin O is a target of the immune response to Listeria monocytogenes. The Journal of Experimental Medicine 1992, 175(6):1467.
39. Hess J., Gentschev I., Miko D., Welzel M., Ladel C., Goebel W., et al. Superior efficacy of secreted over somatic antigen display in recombinant Salmonella vaccine induced protection against listeriosis. Proceedings of the National Academy of Sciences of the United States of America 1996, 93(4):1458.
40. Safley S.A., Cluff C.W., Marshall N.E., Ziegler H.K. Role of listeriolysin-O (LLO) in the T lymphocyte response to infection with Listeria monocytogenes. Identification of T cell epitopes of LLO. The Journal of Immunology 1991, 146(10):3604.
41. Barry R., Bouwer H., Portnoy D., Hinrichs D. Pathogenicity and immunogenicity of Listeria monocytogenes small-plaque mutants defective for intracellular growth and cell-to-cell spread. Infection and Immunity 1992, 60(4):1625.
42. Berche P., Gaillard J., Sansonetti P. Intracellular growth of Listeria monocytogenes as a prerequisite for in vivo induction of T cell-mediated immunity. The Journal of Immunology 1987, 138(7):2266.
43. Hiltbold E., Ziegler H. Mechanisms of processing and presentation of the antigens of Listeria monocytogenes. Infectious Agents and Disease 1993, 2(5):314.
44. Hiltbold E.M., Safley S.A., Ziegler H.K. The presentation of class I and class II epitopes of listeriolysin O is regulated by intracellular localization and by intercellular spread of Listeria monocytogenes. The Journal of Immunology 1996, 157(3):1163.
45. Bahey-El-Din M., Casey P.G., Griffin B.T., Gahan C.G.M. Lactococcus lactis-expressing listeriolysin O (LLO) provides protection and specific CD8+ T cells against Listeria monocytogenes in the murine infection model. Vaccine 2008, 26(41):5304-5314.
46. Sirard J.C., Fayolle C., de Chastellier C., Mock M., Leclerc C., Berche P. Intracytoplasmic delivery of listeriolysin O by a vaccinal strain of Bacillus anthracis induces CD8-mediated protection against Listeria monocytogenes. The Journal of Immunology 1997, 159(9):4435.
47. Pamer E., Cresswell P. Mechanisms of MHC class I-restricted antigen processing. Annual Review of Immunology 1998, 16(1):323-358.
48. De Groot A.S., McMurry J., Marcon L., Franco J., Rivera D., Kutzler M., et al. Developing an epitope-driven tuberculosis (TB) vaccine. Vaccine 2005, 23(17-18):2121-2131.
49. Wang L.X., Nagata T., Tsujimura K., Uchijima M., Seto S., Koide Y. Identification of HLA-DR4-restricted T-cell epitope on MPT51 protein, a major secreted protein derived from Mycobacterium tuberculosis using MPT51 overlapping peptides screening and DNA vaccination. Vaccine 2010, 28(8):2026-2031.
50. Aoshi T., Nagata T., Suzuki M., Uchijima M., Hashimoto D., Rafiei A., et al. Identification of an HLA-A*0201-restricted T-cell epitope on the MPT51 protein, a major secreted protein derived from Mycobacterium tuberculosis, by MPT51 overlapping peptide screening. Infection and Immunity 2008, 76(4):1565.
51. Simossis V., Heringa J. PRALINE: a multiple sequence alignment toolbox that integrates homology-extended and secondary structure information. Nucleic Acids Research 2005, 33(Web Server Issue):W289.
52. Gasteiger E., Hoogland C., Gattiker A., Duvaud S., Wilkins M.R., Appel R.D., et al. Protein identification and analysis tools on the ExPASy server. The proteomics protocols handbook 2005, p. 571-607.
53. Reche P.A., Reinherz E.L. Prediction of peptide-MHC binding using profiles. Methods in Molecular Biology (Clifton then Totowa) 2007, 409:185.
54. Singh H., Raghava G. ProPred1: prediction of promiscuous MHC Class-I binding sites. Bioinformatics 2003, 19(8):1009.
55. Bhasin M., Raghava G.P.S. A hybrid approach for predicting promiscuous MHC class I restricted T cell epitopes. Journal of Biosciences 2007, 32(1):31-42.
56. Hakenberg J., Nussbaum A.K., Schild H., Rammensee H.G., Kuttler C., Holzhütter H.G., et al. MAPPP: MHC class I antigenic peptide processing prediction. Applied Bioinformatics 2003, 2(3):155.
57. Bhasin M, Raghava G. HLAPred: identification and prediction of HLA class I & II binders. http://www.imtech.res.in/raghava/hlapred.
58. Parker K.C., Bednarek M.A., Coligan J.E. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. The Journal of Immunology 1994, 152(1):163.
59. Bhasin M., Raghava G. Prediction of CTL epitopes using QM, SVM and ANN techniques. Vaccine 2004, 22(23-24):3195-3204.
60. Saha S., Raghava G. AlgPred:prediction of allergenic proteins and mapping of IgE epitopes. Nucleic Acids Research 2006, 34(Suppl. 2):W202.
61. Yu C.S., Chen Y.C., Lu C.H., Hwang J.K. Prediction of protein subcellular localization. Proteins: Structure, Function, and Bioinformatics 2006, 64(3):643-651.
62. Brady S., Shatkay H. EpiLoc: a (working) text-based system for predicting protein subcellular location. Citeseer 2008, 15. 2008.
63. Chou K.C., Shen H.B. Euk-mPLoc: a fusion classifier for large-scale eukaryotic protein subcellular location prediction by incorporating multiple sites. J Proteome Res 2007, 6(5):1728-1734.
64. Chou K.C., Shen H.B. Cell-PLoc: a package of Web servers for predicting subcellular localization of proteins in various organisms. Nature protocols 2008, 3(2):153-162.
65. Laurila K., Vihinen M. Prediction of disease-related mutations affecting protein localization. BMC Genomics 2009, 10(1):122.
66. Huang W.L., Tung C.W., Ho S.W., Hwang S.F., Ho S.Y. ProLoc-G.O: utilizing informative Gene Ontology terms for sequence-based prediction of protein subcellular localization. BMC Bioinformatics 2008, 9(1):80.
67. Briesemeister S., Blum T., Brady S., Lam Y., Kohlbacher O., Shatkay H. SherLoc2: a high-accuracy hybrid method for predicting subcellular localization of proteins. Journal of Proteome Research 2009, 8(11):5363-5366.
68. Tamura T., Akutsu T. Subcellular location prediction of proteins using support vector machines with alignment of block sequences utilizing amino acid composition. BMC Bioinformatics 2007, 8(1):466.
69. Matsuda S., Vert J.P., Saigo H., Ueda N., Toh H., Akutsu T. A novel representation of protein sequences for prediction of subcellular location using support vector machines. Protein Science 2005, 14(11):2804-2813.
70. Briesemeister S., Rahnenfuhrer J., Kohlbacher O. Going from where to why - interpretable prediction of protein subcellular localization. Bioinformatics 2010, 26(9):1232.
71. Briesemeister S., Rahnenfuhrer J., Kohlbacher O. YLoc - an interpretable web server for predicting subcellular localization. Nucleic Acids Research 2010, 38(Web Server Issue):W497.
72. Zuker M. Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Research 2003, 31(13):3406.
73. Julenius K. NetCGlyc 1.0: prediction of mammalian C-mannosylation sites. Glycobiology 2007, 17(8):868.
74. Julenius K., Molgaard A., Gupta R., Brunak S. Prediction, conservation analysis, and structural characterization of mammalian mucin-type O-glycosylation sites. Glycobiology 2005, 15(2):153.
75. Johansen M.B., Kiemer L., Brunak S. Analysis and prediction of mammalian protein glycation. Glycobiology 2006, 16(9):844.
76. Gupta R, Jung E, Brunak S. Prediction of N-glycosylation sites in human proteins. The web tool is located at http://www.cbs.dtu.dk/services/NetNGlyc/.
77. Gupta R., Brunak S. Prediction of glycosylation across the human proteome and the correlation to protein function. Citeseer 2002, 310-322.
78. Bologna G., Yvon C., Duvaud S., Veuthey A.L. N terminal myristoylation predictions by ensembles of neural networks. Proteomics 2004, 4(6):1626-1632.
79. Blom N., Gammeltoft S., Brunak S. Sequence and structure-based prediction of eukaryotic protein phosphorylation sites 1. Journal of Molecular Biology 1999, 294(5):1351-1362.
80. Blom N., Sicheritz-Pontén T., Gupta R., Gammeltoft S., Brunak S. Prediction of post-translational glycosylation and phosphorylation of proteins from the amino acid sequence. Proteomics 2004, 4(6):1633-1649.
81. Xue Y., Ren J., Gao X., Jin C., Wen L., Yao X. GPS 2.0, a tool to predict kinase-specific phosphorylation sites in hierarchy. Molecular & Cellular Proteomics 2008, 7(9):1598.
82. Whitton J., Sheng N., Oldstone M., McKee T. A " string-of-beads" vaccine, comprising linked minigenes, confers protection from lethal-dose virus challenge. Journal of Virology 1993, 67(1):348.
83. Thomson S.A., Sherritt M.A., Medveczky J., Elliott S.L., Moss D.J., Fernando G.J.P., et al. Delivery of multiple CD8 cytotoxic T cell epitopes by DNA vaccination. The Journal of Immunology 1998, 160(4):1717.
84. Xia C., Wen-huan X., Juan X., Dan Z., Ying-wei W. Construction and expression of multiepitope DNA vaccine on ESAT-6 antigen of Mycobacterium tuberculosis in vitro. Acta Universitatis Medicinalis Nanjing (Natural Science) 2008, 04.
85. Díaz I., Pujols J., Ganges L., Gimeno M., Darwich L., Domingo M., et al. In silico prediction and ex vivo evaluation of potential T-cell epitopes in glycoproteins 4 and 5 and nucleocapsid protein of genotype-I (European) of porcine reproductive and respiratory syndrome virus. Vaccine 2009, 27(41):5603-5611.
86. Pamer E.G. Immune responses to Listeria monocytogenes. Nature Reviews Immunology 2004, 4(10):812-823.
87. Engelhard V.H., Brickner A.G., Zarling A.L. Insights into antigen processing gained by direct analysis of the naturally processed class I MHC associated peptide repertoire. Molecular Immunology 2002, 39(3-4):127-137.
88. Rock K.L., York I.A., Saric T., Goldberg A.L. Protein degradation and the generation of MHC class I-presented peptides. Advances in Immunology 2002, 80:1-70.
89. Bachmair A., Finley D., Varshavsky A. In vivo half-life of a protein is a function of its amino-terminal residue. Science 1986, 234(4773):179.
90. Gonda D., Bachmair A., Wünning I., Tobias J., Lane W., Varshavsky A. Universality and structure of the N-end rule. Journal of Biological Chemistry 1989, 264(28):16700.
91. Tobias J.W., Shrader T.E., Rocap G., Varshavsky A. The N-end rule in bacteria. Science 1991, 254(5036):1374.
92. Varshavsky A. The N end rule pathway of protein degradation. Genes to Cells 1997, 2(1):13-28.
93. Smyth C., Duncan J. Thiol-activated (oxygen-labile) cytolysins 1978.
94. Alouf J.E., Geoffroy C. The family of the antigenically-related, cholesterol-binding ('sulphydryl-activated') cytolytic toxins. Sourcebook of bacterial protein toxins 1991, p. 147-87.
95. Wolkers M.C., Toebes M., Okabe M., Haanen J.B.A.G., Schumacher T.N.M. Optimizing the efficacy of epitope-directed DNA vaccination. The Journal of Immunology 2002, 168(10):4998.
96. Krieg A.M., Yi A.K., Matson S., Waldschmidt T.J., Bishop G.A., Teasdale R., et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995, 374(6522):546-549.
97. Jakob T., Walker P.S., Krieg A.M., Udey M.C., Vogel J.C. Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA. The Journal of Immunology 1998, 161(6):3042.
98. Bird A.P. CpG islands as gene markers in the vertebrate nucleus. Trends in Genetics 1987, 3:342-347.
99. Bauer S., Wagner H. Bacterial CpG-DNA licenses TLR9. Current Topics in Microbiology and Immunology 2002, 270:145.
100. Verthelyi D., Kenney R.T., Seder R.A., Gam A.A., Friedag B., Klinman D.M. CpG oligodeoxynucleotides as vaccine adjuvants in primates. The Journal of Immunology 2002, 168(4):1659.
101. Krieg A.M., Wu T., Weeratna R., Efler S.M., Love-Homan L., Yang L., et al. Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs. Proceedings of the National Academy of Sciences of the United States of America 1998, 95(21):12631.
102. Klinman D., Yi A., Beaucage S., Conover J., Krieg A. CpG motifs expressed by bacterial DNA rapidly induce lymphocytes to secrete IL-6, IL-12 and IFN {gamma}. Proceedings of the National Academy of Sciences of the United States of America 1996, 93(7):2879-2883.
103. Yamamoto S., Yamamoto T., Shimada S., Kuramoto E., Yano O., Kataoka T., et al. DNA from bacteria, but not from vertebrates, induces interferons, activates natural killer cells and inhibits tumor growth. Microbiology and Immunology 1992, 36(9):983.
104. Messina J., Gilkeson G., Pisetsky D. Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA. The Journal of Immunology 1991, 147(6):1759.
105. Weiner G.J., Liu H.M., Wooldridge J.E., Dahle C.E., Krieg A.M. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proceedings of the National Academy of Sciences of the United States of America 1997, 94(20):10833.
106. Sparwasser T., Koch E.S., Vabulas R.M., Heeg K., Lipford G.B., Ellwart J.W., et al. Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. European Journal of Immunology 1998, 28(6):2045-2054.
107. Roman M., Martin-Orozco E., Goodman J.S., Nguyen M.D., Sato Y., Ronaghy A., et al. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nature Medicine 1997, 3(8):849-854.
108. Klinman D.M. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nature Reviews Immunology 2004, 4(4):249-259.
109. Klinman D.M., Currie D., Gursel I., Verthelyi D. Use of CpG oligodeoxynucleotides as immune adjuvants. Immunological Reviews 2004, 199(1):201-216.
110. Vollmer J., Krieg A.M. Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. Advanced Drug Delivery Reviews 2009, 61(3):195-204.
111. Qiu J.T., Liu B., Tian C., Pavlakis G.N., Yu X.F. Enhancement of primary and secondary cellular immune responses against human immunodeficiency virus type 1 gag by using DNA expression vectors that target Gag antigen to the secretory pathway. Journal of Virology 2000, 74(13):5997.
112. Guhaniyogi J., Brewer G. Regulation of mRNA stability in mammalian cells. Gene 2001, 265(1-2):11-23.
113. Wu X., Jörnvall H., Berndt K.D., Oppermann U. Codon optimization reveals critical factors for high level expression of two rare codon genes in Escherichia coli: RNA stability and secondary structure but not tRNA abundance. Biochemical and Biophysical Research Communications 2004, 313(1):89-96.
114. De Valdivia E.I.G, Isaksson L.A. Abortive translation caused by peptidyl tRNA drop off at NGG codons in the early coding region of mRNA. FEBS Journal 2005, 272(20):5306-5316.
115. Strugnell R., Drew D., Mercieca J., DiNatale S., Firez N., Dunstan S., et al. DNA vaccines for bacterial infections. Immunology and Cell Biology 1997, 75(4):364-369.
116. Kowalczyk D., Ertl H. Immune responses to DNA vaccines. Cellular and Molecular Life Sciences 1999, 55(5):751-770.
117. Bolmstedt A., Hinkula J., Rowcliffe E., Biller M., Wahren B., Olofsson S. Enhanced immunogenicity of a human immunodeficiency virus type 1 env DNA vaccine by manipulating N-glycosylation signals: effects of elimination of the V3 N306 glycan. Vaccine 2001, 20(3-4):397-405.
118. Bright R.A., Ross T.M., Subbarao K., Robinson H.L., Katz J.M. Impact of glycosylation on the immunogenicity of a DNA-based influenza H5 HA vaccine. Virology 2003, 308(2):270-278.
119. Dowling W., Thompson E., Badger C., Mellquist J.L., Garrison A.R., Smith J.M., et al. Influences of glycosylation on antigenicity, immunogenicity, and protective efficacy of Ebola virus GP DNA vaccines. Journal of Virology 2007, 81(4):1821.
120. Aiken C., Konner J., Landau N.R., Lenburg M.E., Trono D. Nef induces CD4 endocytosis: requirement for a critical dileucine motif in the membrane-proximal CD4 cytoplasmic domain. Cell 1994, 76(5):853-864.
121. Rodriguez F., Zhang J., Whitton J.L. DNA immunization: ubiquitination of a viral protein enhances cytotoxic T-lymphocyte induction and antiviral protection but abrogates antibody induction. Journal of Virology 1997, 71(11):8497.
122. Tobery T.W., Siliciano R.F. Targeting of HIV-1 antigens for rapid intracellular degradation enhances cytotoxic T lymphocyte (CTL) recognition and the induction of de novo CTL responses in vivo after immunization. The Journal of Experimental Medicine 1997, 185(5):909.
123. Hochstrasser M. Ubiquitin-dependent protein degradation. Annual Review of Genetics 1996, 30(1):405-439.
124. Montgomery D.L., Prather K.J. Design of plasmid DNA constructs for vaccines. Methods in Molecular Medicine 2006, 127:11.
125. Alarcon J.B., Waine G.W., McManus D.P. DNA vaccines: technology and application as anti-parasite and anti-microbial agents. Advances in Parasitology 1999, 42:343-410.
126. Leitner W.W., Seguin M.C., Ballou W.R., Seitz J.P., Schultz A.M., Sheehy M.J., et al. Immune responses induced by intramuscular or gene gun injection of protective deoxyribonucleic acid vaccines that express the circumsporozoite protein from Plasmodium berghei malaria parasites. The Journal of Immunology 1997, 159(12):6112.
127. Kensil C.R., Patel U., Lennick M., Marciani D. Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex. The Journal of Immunology 1991, 146(2):431.
128. Kensil C., Wu J., Soltysik S. Structural and immunological characterization of the vaccine adjuvant QS-21. Pharmaceutical Biotechnology 1995, 6:525.
129. Chow Y.H., Huang W.L., Chi W., Chu Y.D., Tao M.H. Improvement of hepatitis B virus DNA vaccines by plasmids coexpressing hepatitis B surface antigen and interleukin-2. Journal of Virology 1997, 71(1):169.